Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. The company is headquartered in Los Angeles, California.
| Revenue (TTM) | 20,940 |
| Gross Profit (TTM) | 20,940 |
| EBITDA | $-9.77M |
| Operating Margin | -6815.00% |
| Return on Equity | -325.50% |
| Return on Assets | -9.65% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-2.14 |
| Price-to-Book | 0.48 |
| Price-to-Sales (TTM) | 610.52 |
| EV/Revenue | 608.44 |
| EV/EBITDA | -7.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.53M |
| Float | $3.35M |
| % Insiders | 31.30% |
| % Institutions | 2.76% |
Volatility is currently contracting
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.
Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development SACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases.
WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market in late 2025 and throughout the first half of 2026. Co-lead counsel, Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from the 'naked' short sellers who have caused real market harm to Lunai and its shareholders.
SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-8 (the "Reverse Stock Split").
WASHINGTON, D.C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms' client, Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai), alleging securities fraud (stock manipulation) and intentional tort against “John Doe” “naked” short sellers of Lunai common stock on the Nasdaq Stock Market. The Complaint alleges that the short sellers engaged in the unlawful practice of “naked short selling” in a coordinated and systematic scheme to cause substantial harm to the company and its shareholders – highlighting deceptive devices they employed to violate federal laws and regulations and avoid detection by regulators. The lawsuit, filed in federal court in Delaware, seeks unspecified compensatory and special damages and other relief.
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications SACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies.
Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies.
Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deployment SACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven drug discovery and biodefense company, today announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements currently under discussion.
SACRAMENTO, Calif., March 26, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's drug assets from the Clemann Group, SAS or its assignee.
